Healthcare provider profile · identity verified

Mark A. Ringiewicz, M.D.

Family Practice · SWANSEA, MA · NPI 1669432605

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Lisinopril	Lisinopril	386	106
Atorvastatin Calcium	Atorvastatin Calcium	317	99
Amlodipine Besylate	Amlodipine Besylate	244	66
Omeprazole	Omeprazole	218	64
Metoprolol Succinate	Metoprolol Succinate	207	50
Metformin Hcl	Metformin Hcl	204	51
Hydrochlorothiazide	Hydrochlorothiazide	192	59
Losartan Potassium	Losartan Potassium	155	42
Lorazepam	Lorazepam	152	39
Citalopram Hbr	Citalopram Hydrobromide	128	32
Gabapentin	Gabapentin	128	36
Levothyroxine Sodium	Levothyroxine Sodium	127	33
Oxycodone Hcl	Oxycodone Hcl	124	22
Rosuvastatin Calcium	Rosuvastatin Calcium	123	41
Eliquis	Apixaban	113	19
Pantoprazole Sodium	Pantoprazole Sodium	102	34
Tramadol Hcl	Tramadol Hcl	98	19
Simvastatin	Simvastatin	96	28
Sertraline Hcl	Sertraline Hcl	90	25
Furosemide	Furosemide	87	29
Albuterol Sulfate Hfa	Albuterol Sulfate	84	30
Allopurinol	Allopurinol	83	20
Trazodone Hcl	Trazodone Hcl	82	22
Prednisone	Prednisone	77	57
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	76	27
Doxycycline Hyclate	Doxycycline Hyclate	75	65
Metformin Hcl Er	Metformin Hcl	69	16
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	68	12
Zolpidem Tartrate	Zolpidem Tartrate	64	suppressed
Alprazolam	Alprazolam	62	suppressed
Meloxicam	Meloxicam	59	14
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	58	12
Tamsulosin Hcl	Tamsulosin Hcl	56	16
Clopidogrel	Clopidogrel Bisulfate	54	11
Glipizide	Glipizide	54	13
Atenolol	Atenolol	53	16
Chlorthalidone	Chlorthalidone	53	13
Ibuprofen	Ibuprofen	49	12
Metoprolol Tartrate	Metoprolol Tartrate	48	18
Testosterone Cypionate	Testosterone Cypionate	47	suppressed
Clonazepam	Clonazepam	46	11
Clonidine Hcl	Clonidine Hcl	46	12
Buspirone Hcl	Buspirone Hcl	42	suppressed
Fluticasone Propionate	Fluticasone Propionate	42	16
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	41	suppressed
Labetalol Hcl	Labetalol Hcl	40	suppressed
Jardiance	Empagliflozin	39	suppressed
Montelukast Sodium	Montelukast Sodium	39	11
Amitriptyline Hcl	Amitriptyline Hcl	37	suppressed
Potassium Chloride	Potassium Chloride	37	11
Ezetimibe	Ezetimibe	36	11
Januvia	Sitagliptin Phosphate	35	suppressed
Diazepam	Diazepam	34	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	34	suppressed
Pravastatin Sodium	Pravastatin Sodium	33	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	33	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	33	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	30	15
Ozempic	Semaglutide	30	suppressed
Donepezil Hcl	Donepezil Hcl	29	suppressed
Famotidine	Famotidine	29	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	29	15
Pregabalin	Pregabalin	28	suppressed
Finasteride	Finasteride	27	suppressed
Ondansetron Hcl	Ondansetron Hcl	27	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	25	suppressed
Nifedipine Er	Nifedipine	25	suppressed
Tizanidine Hcl	Tizanidine Hcl	25	suppressed
Amoxicillin	Amoxicillin	23	17
Bupropion Xl	Bupropion Hcl	23	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	23	suppressed
Cephalexin	Cephalexin	22	18
Combivent Respimat	Ipratropium/Albuterol Sulfate	22	suppressed
Duloxetine Hcl	Duloxetine Hcl	22	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	21	suppressed
Ventolin Hfa	Albuterol Sulfate	21	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	20	suppressed
Topiramate	Topiramate	20	suppressed
Paroxetine Hcl	Paroxetine Hcl	19	suppressed
Acyclovir	Acyclovir	18	suppressed
Dextroamphetamine-Amphet Er	Dextroamphetamine/Amphetamine	18	suppressed
Humalog Kwikpen U-100	Insulin Lispro	18	suppressed
Mirtazapine	Mirtazapine	18	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	18	suppressed
Carvedilol	Carvedilol	17	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	17	16
Ondansetron Odt	Ondansetron	17	suppressed
Prochlorperazine Maleate	Prochlorperazine Maleate	17	suppressed
Glimepiride	Glimepiride	16	suppressed
Glipizide Er	Glipizide	16	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	16	16
Warfarin Sodium	Warfarin Sodium	16	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	15	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	15	suppressed
Morphine Sulfate Er	Morphine Sulfate	15	suppressed
Torsemide	Torsemide	15	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	14	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	14	suppressed
Olanzapine	Olanzapine	14	suppressed
Synthroid	Levothyroxine Sodium	14	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	13	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	13	suppressed
Spironolactone	Spironolactone	13	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	13	suppressed
Trulicity	Dulaglutide	13	suppressed
Baclofen	Baclofen	12	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	12	suppressed
Oxycontin	Oxycodone Hcl	12	suppressed
Propranolol Hcl Er	Propranolol Hcl	12	suppressed
Terazosin Hcl	Terazosin Hcl	12	suppressed
Fentanyl	Fentanyl	11	suppressed
Hydromorphone Hcl	Hydromorphone Hcl	11	suppressed
Indomethacin	Indomethacin	11	suppressed
Morphine Sulfate	Morphine Sulfate	11	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	11	suppressed
Valacyclovir	Valacyclovir Hcl	11	suppressed
Zolpidem Tartrate Er	Zolpidem Tartrate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error